CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Novo Nordisk A/S (NYSE: NVO) shares jumped nearly 8% in after-hours trading on Monday following a major regulatory milestone: the U.S. Food and Drug Administration approved the company’s Wegovy pill, making it the first oral GLP-1 receptor agonist authorized for chronic weight management. The approval marks a significant expansion of Novo Nordisk’s obesity treatment portfolio and could reshape the competitive landscape of the global weight loss market.
The newly approved Wegovy pill contains once-daily oral semaglutide 25 mg and is designed for adults with obesity or overweight who have at least one weight-related comorbidity. Clinical data supporting the FDA decision came primarily from the OASIS 4 trial, a 64-week, randomized, placebo-controlled study involving 307 participants. Results showed a mean weight loss of 16.6% among patients who adhered to treatment, a level comparable to the weight reduction achieved with the injectable Wegovy 2.4 mg formulation. Notably, about one in three participants achieved weight loss of 20% or more during the trial.
Beyond weight reduction, the FDA approval also includes indications to help patients maintain long-term weight loss and reduce the risk of major adverse cardiovascular events. The safety and tolerability profile of the Wegovy pill was consistent with previous semaglutide trials, reinforcing confidence in its clinical use. Gastrointestinal side effects observed were in line with those already known for GLP-1 receptor agonists.
“The pill is here. With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” said Mike Doustdar, president and CEO of Novo Nordisk. His comments highlight the potential appeal of an oral alternative for patients who prefer not to use injections.
Novo Nordisk plans to launch the Wegovy pill in the United States in early January 2026. The company has also submitted regulatory applications to the European Medicines Agency and other global authorities in the second half of 2025. The broader OASIS clinical development program included four trials enrolling around 1,300 adults, underscoring the company’s long-term commitment to expanding access to effective obesity treatments worldwide.
